Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

460 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeting c-MYC and gain-of-function p53 through inhibition or degradation of the kinase LZK suppresses the growth of HNSCC tumors.
Funk AL, Katerji M, Afifi M, Nyswaner K, Woodroofe CC, Edwards ZC, Lindberg E, Bergman KL, Gough NR, Rubin MR, Karpińska K, Trotter EW, Dash S, Ries AL, James A, Robinson CM, Difilippantonio S, Karim BO, Chang TC, Chen L, Xu X, Doroshow JH, Ahel I, Marusiak AA, Swenson RE, Cappell SD, Brognard J. Funk AL, et al. Among authors: doroshow jh. Sci Signal. 2025 Feb 11;18(873):eado2857. doi: 10.1126/scisignal.ado2857. Epub 2025 Feb 11. Sci Signal. 2025. PMID: 39933019
Phase 1 studies of the indenoisoquinolines LMP776 and LMP744 in patients with solid tumors and lymphomas.
O'Sullivan Coyne G, Kummar S, Rubinstein LV, Wilsker D, Moore N, Hogu M, Piekarz R, Covey J, Beumer JH, Ferry-Galow KV, Villaruz LC, Hollingshead MG, Holleran JL, Deppas JJ, Pommier Y, Ko B, Johnson BC, Parchhment RE, Ivy P, Doroshow JH, Chen AP. O'Sullivan Coyne G, et al. Among authors: doroshow jh. Cancer Chemother Pharmacol. 2025 May 29;95(1):58. doi: 10.1007/s00280-025-04778-5. Cancer Chemother Pharmacol. 2025. PMID: 40439882 Free PMC article. Clinical Trial.
Preclinical NCI-MPACT: prospective modeling of the mutation-based NCI-MPACT clinical trial therapeutic strategy in patient-derived xenograft models.
Evrard YA, Alcoser SY, Mullendore M, Chen L, Lih CJ, Kannan VR, Datta V, Dutko L, Jiwani S, Rubinstein LV, Zhao Y, Williams PM, Palmisano A, Kuhlmann L, Simpson M, Kummar S, Das B, Karlovich C, Polley E, Li MC, Chen AP, Hollingshead MG, Doroshow JH. Evrard YA, et al. Among authors: doroshow jh. Front Oncol. 2025 May 19;15:1571635. doi: 10.3389/fonc.2025.1571635. eCollection 2025. Front Oncol. 2025. PMID: 40458731 Free PMC article.
NCI workshop on ctDNA in cancer treatment and clinical care.
Sorg BS, Byun JS, Westbrook VA, Tricoli JV, Doroshow JH, Harris LN. Sorg BS, et al. Among authors: doroshow jh. J Natl Cancer Inst. 2024 Dec 1;116(12):1890-1895. doi: 10.1093/jnci/djae179. J Natl Cancer Inst. 2024. PMID: 39087596 Free PMC article.
Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial.
Gross AM, O'Sullivan Coyne G, Dombi E, Tibery C, Herrick WG, Martin S, Angus SP, Shern JF, Rhodes SD, Foster JC, Rubinstein LV, Baldwin A, Davis C, Dixon SAH, Fagan M, Ong MJ, Wolters PL, Tamula MA, Reid O, Sankaran H, Fang F, Govindharajulu JP, Browne AT, Kaplan RN, Heisey K, On TJ, Xuei X, Zhang X, Johnson BC, Parchment RE, Clapp DW, Srivastava AK, Doroshow JH, Chen AP, Widemann BC. Gross AM, et al. Among authors: doroshow jh. Nat Med. 2025 Jan;31(1):105-115. doi: 10.1038/s41591-024-03361-4. Epub 2025 Jan 6. Nat Med. 2025. PMID: 39762421 Clinical Trial.
460 results